寻找阿尔茨海默氏症保护基因的搜索策略
1The Neuroscience Research Institute and The Department of Molecular Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, California, USA.
Annals of neurology
|August 14, 2023
概括
研究人员确定了特定的家庭结构和遗传背景,理想用于发现抗阿尔茨海默病的保护性基因变异. 这项研究可能会发现神经退行性疾病的新治疗点.
科学领域:
- 神经遗传学 神经遗传学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 自体主导性阿尔茨海默氏病 (ADAD) 家庭可能存在保护性基因变异.
- 目前还没有系统的方法来识别这些保护变体.
- 了解保护机制对于开发新型AD疗法至关重要.
研究的目的:
- 描述在ADAD中发现保护变异的最佳人口和遗传条件.
- 为这些保护性基因的系统搜索策略奠定基础.
主要方法:
- 在大型ADAD血统中分析独特的家族结构和遗传背景.
- 审查现有的文献和遗传数据,以确定与保护相关的模式.
主要成果:
- 定义了特定的家族和遗传环境,有利于识别保护变异.
- 突出了这些设置加速发现保护基因的潜力.
结论:
- 在ADAD中识别保护基因可以为ADAD的病原体提供关键的见解.
- 这种战略方法可能会揭示阿尔茨海默病和相关痴呆症的新疗法途径.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
01:26Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215